The relationship between the levels of serum acute phase reactant proteins (a1-acid glycoprotein, a,-antitrypsin, haptoglobin) was investigated in patients with glioblastoma multiforme in relation to their prognosis. a,-acid glycoprotein was higher in the patients who died within one year after admission than in those with a longer survival time. It is suggested that serum al-acid glycoprotein profiles provide prognostic information in patients with glioblastoma multiforme. The determination of a,-acid glycoprotein, a,-antitrypsin and haptoglobin was by the single radial immunodiffusion method (Hoechst Japan Co, Tokyo). The PPD skin test was performed prior to treatment to evaluate the cellular immune competence of the patients. PPD (0.05 ,ug/0 1 ml) was injected subcutaneously into the forearm, and the flare reaction of the skin was examined 48 hours later. Erythema of more than 10 mm in diameter with a distinct indurated margin was regarded as positive. All patients were treated with surgical operation (subtotal removal of the tumour), anticancer drugs (ACNU 100 mg, vincristine 1 mg) and radiation (5000 rads).
within one year after admission than in those with a longer survival time. It is suggested that serum al-acid glycoprotein profiles provide prognostic information in patients with glioblastoma multiforme.
Serum acute phase reactant proteins (APRPs) increase in cancer patients as well as in those with acute and chronic inflammation, trauma and autoimmune diseases.'-3 Since the levels of APRPs correlate closely with the extent of disease, it appears that these proteins have immunological properties which affect a host's defences against tumours.48 However, there have been few studies on APRPs in patients with brain tumours,9 and no reports concerning the relationship between the serum concentration of APRPs and the spread of disease or the host's immunological competence.
To investigate the relationship between the serum concentration of APRPs in glioma patients and the host-tumour response, we measured several APRPs in addition to performing the purified protein derivative (PPD) skin test.
Subjects and methods
Sixteen patients (8 males and 8 females) with glioblastoma multiforme were studied, aged from 20 to 66 years. They had no concomitant disease and were diagnosed on the basis of the histological findings after surgery. Nine healthy volunteers with age and sex distributions similar to those of the patients were used as controls. Blood specimens were collected by peripheral venipuncture prior to treatment.
The determination of a,-acid glycoprotein, a,-antitrypsin and haptoglobin was by the single radial immunodiffusion method (Hoechst Japan Co, Tokyo). The PPD skin test was performed prior to treatment to evaluate the cellular immune competence of the patients. PPD (0.05 ,ug/0 1 ml) was injected subcutaneously into the forearm, and the flare reaction of the skin was examined 48 hours later. Erythema of more than 10 mm in diameter with a distinct indurated margin was regarded as positive. All patients were treated with surgical operation (subtotal removal of the tumour), anticancer drugs (ACNU 100 mg, vincristine 1 mg) and radiation (5000 rads).
The patients were divided evenly into two groups. Those who died within one year after the time of determination of the APRPs and PPD skin test (Group 1), and those who survived more than one year (Group 2). The APRP levels and PPD skin test results were compared between these two groups, and the data were analysed by Student' s t test.
Results
Elevated levels of al-acid glycoprotein, a, antitrypsin and haptoglobin were seen in the patients compared with the normal controls (table). As shown in the figure, the al-acid glycoprotein level was higher in Group 1 than in Group 2. The a,-antitrypsin and haptoglobin levels were higher in Group 1, but not significantly. The PPD skin test was negative in seven out of eight cases in Group 1 835 
